Evrofarma SA produces and sells dairy products in Greece.
+ 2 more risks
Mediocre balance sheet with poor track record.
Share Price & News
How has Evrofarma's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: EVROF's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: EVROF exceeded the Greek Food industry which returned 1.2% over the past year.
Return vs Market: EVROF exceeded the Greek Market which returned -24.4% over the past year.
Price Volatility Vs. Market
How volatile is Evrofarma's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StHere's What Evrofarma SA's (ATH:EVROF) P/E Is Telling Us
1 month ago | Simply Wall StIs Evrofarma (ATH:EVROF) A Risky Investment?
2 months ago | Simply Wall StAnnouncing: Evrofarma (ATH:EVROF) Stock Soared An Exciting 414% In The Last Five Years
Is Evrofarma undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: EVROF (€0.84) is trading above our estimate of fair value (€0)
Significantly Below Fair Value: EVROF is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: EVROF is poor value based on its PE Ratio (20.6x) compared to the Food industry average (15.5x).
PE vs Market: EVROF is poor value based on its PE Ratio (20.6x) compared to the Greek market (11.6x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate EVROF's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: EVROF is overvalued based on its PB Ratio (1x) compared to the GR Food industry average (0.7x).
How is Evrofarma forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Food, Beverage & Tobacco industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Evrofarma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Take a look at our analysis of EVROF’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- Evrofarma competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Food, Beverage & Tobacco industry.
How has Evrofarma performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: EVROF has a large one-off loss of €455.0K impacting its June 30 2019 financial results.
Growing Profit Margin: EVROF's current net profit margins (1.6%) are lower than last year (2.9%).
Past Earnings Growth Analysis
Earnings Trend: EVROF has become profitable over the past 5 years, growing earnings by 36.1% per year.
Accelerating Growth: EVROF's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: EVROF had negative earnings growth (-38.7%) over the past year, making it difficult to compare to the Food industry average (5.3%).
Return on Equity
High ROE: EVROF's Return on Equity (4.7%) is considered low.
How is Evrofarma's financial position?
Financial Position Analysis
Short Term Liabilities: EVROF's short term assets (€17.3M) do not cover its short term liabilities (€17.4M).
Long Term Liabilities: EVROF's short term assets (€17.3M) exceed its long term liabilities (€16.3M).
Debt to Equity History and Analysis
Debt Level: EVROF's debt to equity ratio (149%) is considered high.
Reducing Debt: EVROF's debt to equity ratio has reduced from 245.2% to 149% over the past 5 years.
Debt Coverage: EVROF's debt is not well covered by operating cash flow (5.5%).
Interest Coverage: EVROF's interest payments on its debt are well covered by EBIT (3.6x coverage).
Inventory Level: EVROF has a high level of physical assets or inventory.
Debt Coverage by Assets: EVROF's debt is not covered by short term assets (assets are 1x debt).
What is Evrofarma's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate EVROF's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate EVROF's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if EVROF's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if EVROF's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of EVROF's dividend in 3 years as they are not forecast to pay a notable one for the Greek market.
How experienced are the management team and are they aligned to shareholders interests?
Paschalis Papazilakis (61yo)
Mr. Paschalis H. Papazilakis is the Founder of Evrofarma S.A. and serves as its Vice Chairman and Chief Executive Officer.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Evrofarma SA's company bio, employee growth, exchange listings and data sources
- Name: Evrofarma SA
- Ticker: EVROF
- Exchange: ATSE
- Industry: Packaged Foods and Meats
- Sector: Food, Beverage & Tobacco
- Market Cap: €11.622m
- Shares outstanding: 13.67m
- Website: https://www.evrofarma.gr
- Evrofarma SA
- 10 km Didimoticho - Orestiada
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|EVROF||ATSE (The Athens Stock Exchange)||Yes||Ordinary Shares||GR||EUR||Jun 2000|
Evrofarma SA produces and sells dairy products in Greece. It offers milk and liquids, ayran, cheese and organic cheese, and yogurt. The company also exports its products to 13 countries. Evrofarma SA is based in Didymoteicho, Greece.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/03 20:41|
|End of Day Share Price||2020/04/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.